Medtronic plc filed an 8-K on November 16, 2026, disclosing its intent to acquire Contego Medical, a privately held medical device company focused on carotid artery disease and peripheral thrombectomy, in a deal valued at $380 million with potential post-acquisition payments.

Key Highlights

  • Deal value: The acquisition is valued at $380 million with potential payments post-acquisition, according to the filing.
  • Expected closing: Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions.
  • EPS impact: The acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and FY28, and neutral to accretive thereafter, the company disclosed.
  • FDA-approved device included: The planned acquisition includes Contego's Neuroguard IEP Direct System, described in the filing as the first and only transcarotid artery revascularization system with integrated embolic protection in addition to flow reversal.
  • PERFORMANCE III study results: In the prospective, multicenter PERFORMANCE III study, the Neuroguard IEP Direct System demonstrated zero strokes, zero neurological deaths, zero cranial nerve injuries, and zero myocardial infarctions at 30 days.
  • Prior commercial relationship: The acquisition builds on an exclusive U.S. distribution agreement with Contego that was first announced in January 2025, according to the filing.

Medtronic's Planned Acquisition of Contego Medical and Its Carotid Technology Portfolio

According to the filing, Medtronic (NYSE:MDT) announced its intent to acquire Contego Medical, Inc., a privately held company focused on carotid artery disease and peripheral thrombectomy. The deal is valued at $380 million with potential payments post-acquisition. Medtronic disclosed that the acquisition is expected to be minimally dilutive to its adjusted EPS in FY27 and FY28 and neutral to accretive thereafter. Closing is anticipated in the third quarter of Medtronic's fiscal year, subject to customary closing conditions.

The filing states that the planned acquisition includes Contego's recently FDA-approved Neuroguard IEP Direct System, described as the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. In the PERFORMANCE III study, a prospective, multicenter trial, the system reported zero strokes, zero neurological deaths, zero cranial nerve injuries, and zero myocardial infarctions at 30 days. The filing notes that Contego Medical was founded by Ravish Sachar, MD, and Jay Yadav, MD.

Beyond carotid revascularization, the filing discloses that the acquisition also includes Contego's Excipio thrombectomy devices, which the filing states complement Medtronic's Liberant thrombectomy system in the treatment of peripheral vascular disease. The company disclosed that the transaction advances its strategy of "pursuing targeted investments that strengthen the company's core franchises" and expands its portfolio of carotid technologies. The acquisition builds on an exclusive U.S. distribution agreement with Contego that was first announced in January 2025, according to the filing. Medtronic noted that any forward-looking statements are subject to risks and uncertainties described in its periodic reports on file with the SEC, and that actual results may differ materially from anticipated results.

What Was Disclosed

Medtronic disclosed its intent to acquire Contego Medical for $380 million with potential post-acquisition payments. The deal covers Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Closing is expected in Medtronic's third fiscal quarter, subject to customary closing conditions.